Association of renin‐angiotensin‐aldosterone system inhibitors with mortality and testing positive of COVID‐19: Meta‐analysis

Yokoyama, Yujiro; Aikawa, Tadao; Takagi, Hisato; Briasoulis, Alexandros; Kuno, Toshiki

Some have hypothesized that the use of angiotensin‐converting enzyme inhibitors (ACEI) and angiotensin‐receptor blockers (ARB) may modify susceptibility to coronavirus disease‐2019 (COVID‐19) in humans. Thus, we conducted two meta‐analyses to investigate the effect of ACEI and ARB on mortality and susceptibility to COVID‐19. Pubmed and EMBASE were searched through June 2020 to identify clinical trials that investigated the testing positive and in‐hospital mortality rates for COVID‐19 for those who were treated with ACEI and/or ARB and for those who were not treated with ACEI or ARB. The first analysis investigated the testing positive rate of COVID‐19. The second analysis investigated the in‐hospital mortality rate for patients with COVID‐19. Three eligible studies for the first analysis and 14 eligible studies for the second analysis were identified. The first analysis demonstrated that the use of ACEI or ARB did not affect the testing positive rates (odds ratio [OR] [confidence interval [CI]] = 0.96 [0.88–1.04]; p = .69, OR [CI] = 0.99 [0.91–1.08]; p = 0.35, respectively). The second analysis showed that the use of ACEI and/or ARB did not affect in‐hospital mortality (risk ratio [RR] 95% [CI]] = 0.88 [0.64–1.20], p = 0.42). The subgroup analysis by limiting studies of patients with hypertension showed ACEI and/or ARB use was associated with a significant reduction of in‐hospital mortality compared with no ACEI or ARB use (RR [CI] = 0.66 [0.49‐0.89], p = 0.004). Our analysis demonstrated that ACEI and/or ARB use was associated neither with testing positive rates of COVID‐19 nor with mortality of COVID‐19 patients.